- The European Medicines Agency (EMA) designates Oncolytics Biotech's (NASDAQ:ONCY +4.7%) Reolysin (reovirus variant) an Orphan Drug for the treatment of ovarian, fallopian tube and primary peritoneal cancers. If approved, it will have a 10-year period of market exclusivity.
- Reolysin, currently in Phase 2 development, is also an Orphan Drug in the U.S. for the same diseases as well as cancer of the pancreas.